GuidelineArthritis & rheumatology (Hoboken, N.J.)2021
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Guideline in Arthritis & rheumatology (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 319 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
Who cites it
319 citing papers in PubMed, 4 syntheses or guidelines pooled it, 613 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Hepatic granulomas as a manifestation of ANCA-associated vasculitis:a systematic review.Frontiers in immunology · 2026Pooled it
- The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2025Guideline
- Anti-IL5/IL-5 receptor therapies for eosinophilic granulomatosis with polyangiitis: an updated Systematic Review.Frontiers in immunology · 2025Pooled it
- The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide.RMD open · 2025Trial
- Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.Rheumatology (Oxford, England) · 2025Trial
- Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS).American journal of respiratory and critical care medicine · 2024Trial
- Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.Annals of the rheumatic diseases · 2024Trial
- Eosinophilia and the Heart: Evolving Concepts.Current cardiology reports · 2026Review
- Prognostic impact of autoimmune features in interstitial lung disease: a single-center retrospective real-world cohort study.Clinical rheumatology · 2026Article
- Quality and Safety Intervention: Improving Care of Patients Undergoing B Cell-Targeted Therapies.The journal of allergy and clinical immunology. In practice · 2026Article
- Multi-database pharmacovigilance identifies disproportionate reporting of hepatobiliary events with avacopan: an integrative study with network pharmacology and interpretable machine learning.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Association Between Any Circulating ANCA Positivity at Diagnosis and Subsequent End-Stage Kidney Disease in Microscopic Polyangiitis and Granulomatosis with Polyangiitis.Medicina (Kaunas, Lithuania) · 2026Article
- Acute respiratory distress mimickers: a practical approach for intensivists.Intensive care medicine · 2026Article
- Healthcare resource utilisation and associated costs in patients with eosinophilic granulomatosis with polyangiitis in England: A retrospective observational cohort study.The World Allergy Organization journal · 2026Article
- Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases.Pediatric nephrology (Berlin, Germany) · 2026Review
- Accounting for Oral Corticosteroids Tapering and Reduction in Adverse Effect Burden in Health Economic Evaluations: External Assessment Group Perspective.PharmacoEconomics · 2026Article
259 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byReply.2022
- Commented on by
Authors and funding
32 authors at 20 institutions in 2 countries.
Funding
Abstract
objectiveTo provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA).
methodsClinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel.
resultsWe present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations.
conclusionThis guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.